Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Sight Sciences , Inc. (NASDAQ:SGHT) Chief Legal Officer Jeremy B. Hayden, disposed of 9,160 shares of common stock on July 3, 2025. The shares were sold at a price of $4.174, for a total transaction value of $38,233. The transaction occurred amid significant stock volatility, with shares down nearly 15% in the past week and currently trading at $3.48. According to InvestingPro analysis, the company appears undervalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover the reporting person’s tax liability in connection with the vesting of restricted stock units. Following the transaction, Hayden directly owns 266,321 shares of Sight Sciences, Inc., representing a significant stake in the $178 million market cap company. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 10.47 and holds more cash than debt on its balance sheet. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis through the Pro Research Report.
In other recent news, Sight Sciences reported its first-quarter 2025 earnings, revealing a net loss per share of $0.28, which did not meet the expected $0.23. The company also fell short on revenue, reporting $17.5 million compared to the forecasted $18.4 million. Despite these setbacks, the company has reaffirmed its revenue guidance for the full year, projecting between $70 million and $75 million. In a move to bolster its strategic direction, Sight Sciences appointed Gerhard F. Burbach to its Board of Directors and ratified Deloitte & Touche LLP as its independent accounting firm for the fiscal year ending December 31, 2025.
Meanwhile, Piper Sandler has raised its price target for Sight Sciences to $4.00, citing positive factors in the company’s minimally invasive glaucoma surgery technology and dry eye treatment pipeline, although it maintained a Neutral rating due to uncertainties in the glaucoma business. Needham also maintained a Hold rating after Sight Sciences’ first-quarter revenue exceeded consensus expectations, showing optimism about the company’s performance despite some financial challenges. The company is taking strategic steps to address tariff impacts by moving its manufacturing operations out of China over the next nine months. These developments indicate a proactive approach by Sight Sciences as it navigates current market conditions and prepares for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.